Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents

July 19, 2017

Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis

Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents

The Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis which was published in the International journal of antimicrobial agents. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis - International Journal of Antimicrobial Agents Human African trypanosomiasis (HAT) is a neglected tropical disease, with a population of 70 million at risk. Current treatment options are limited.

In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.

For more information please see - https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents

< Older Post

Newer Post >

Ash Alavijeh will be attending the Life Sciences Wallonia Business Forum

October 28, 2025

Pharmidex is pleased to share that Ash Alavijeh , our Head of Operations, will be attending the Life Sciences Wallonia Business Forum this evening at the Residence of the Belgian Ambassador. Hosted by the Economic Counsellor of Belgium-Wallonia Investment & Trade, the event brings together leading organisations across the European life sciences sector to explore how Wallonia supports international growth both financially and strategically. We look forward to connecting with international partners and exploring opportunities for collaboration and innovation in the European life sciences ecosystem.

Pharmidex is proud to sponsor the SMR meeting Target Identification and Validation in Drug Discovery

October 23, 2025

We’re excited that Janette Dalay Robertson (Business Development Manager) and Ian Knowles (Head of Respiratory) will attend, eager to meet attendees, share ideas and explore new collaborations to advance drug discovery and development. At Pharmidex , we know robust target validation is key to successful therapeutics. Our expertise in biomarker analysis, histology, in vivo models, and autoimmune disease research supports innovation across translational medicine.

We present our poster with VasoDynamics at Scotland’s Health R&I Conference

October 22, 2025

Pharmidex is delighted to announce our joint poster with VasoDynamics Ltd at Scotland’s Health Research and Innovation Conference on October 23rd in Edinburgh! We’re proud to be part of this inspiring event, organised by NHS Scotland and CSO Scotland , which brings together the brightest minds driving progress in health research, innovation, and life sciences. 📍 Visit our stand to learn more about our collaborative work. A printout of the poster will be available. Mo Alavijeh (FRSC, FRSM ) is looking forward to meeting attendees and discussing new opportunities for partnership and discovery. Together with VasoDynamics Ltd , we’re advancing science through collaboration and innovation. 🔗 Learn more about Pharmidex : www.pharmidex.com